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doi:10.1016/j.jtcvs.2003.12.023Objectives: Heparin rebound, the reappearance of anticoagulant activity after ade-
quate neutralization with protamine, is thought to contribute to excessive postop-
erative bleeding after cardiac surgery. We have previously demonstrated that a
significant amount of heparin is bound nonspecifically to plasma proteins and is
incompletely neutralized by protamine. The aim of this study was to investigate
whether clinically important bleeding attributable to heparin rebound can be elim-
inated by infusion of small amounts of additional protamine for 6 hours postoper-
atively and whether this treatment can reduce mediastinal blood loss.
Methods: Three hundred patients undergoing elective cardiac surgery were random-
ized to receive either a continuous infusion of protamine sulphate (25 mg/h for 6
hours) postoperatively or saline placebo. Serial blood samples were obtained to
measure thrombin clotting time and anti-factor Xa activity. Heparin bound nonspe-
cifically to plasma proteins was measured after displacement with a chemically
altered heparin with low affinity to antithrombin. Mediastinal blood loss and
transfusion requirements were recorded.
Results: Heparin rebound was demonstrated in every patient in the placebo group as
reflected by increased thrombin clotting time, anti-factor Xa activity, and protein-
bound heparin between 1 and 6 hours after surgery. In contrast, heparin rebound was
eliminated in the protamine infusion group. The thrombin clotting time was nor-
malized and both heparin concentration and protein-bound heparin were almost
undetectable (P  .001). There was a modest 13% reduction in postoperative
bleeding but this did not reduce blood transfusions. No adverse events were
attributable to the extra protamine.
Conclusions: Postoperative protamine infusion was able to almost totally abolish
heparin rebound. In the context of this study, protamine infusion resulted in reduced
postoperative bleeding but the magnitude was insufficient to alter transfusion
requirements.
Cardiopulmonary bypass is an integral component of cardiac sur-gery. Patients undergoing cardiopulmonary bypass surgery whohave significant bleeding after cardiac surgery are at risk of in-creased mortality and morbidity. Protamine sulphate is adminis-tered after cardiopulmonary bypass to neutralize the anticoagulanteffect of heparin, thereby establishing normal hemostasis after
surgery. Hyun and associates1 described the reappearance of hypocoagulability after
adequate neutralization of heparin and coined the phrase “heparin rebound” to
describe this phenomenon. Gollub2 noted that the prolongation of clotting times
postoperatively after initial neutralization could be shortened by the administration
of additional protamine and concluded that the phenomenon was caused by reap-
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incidence of heparin rebound varies widely and has been
reported to be as high as 50%.3
The anticoagulant activity of heparin is mediated by its
binding through a specific pentasaccharide to antithrombin
(AT), which results in a marked accceleration of the rate at
which AT inactivates thrombin, factor Xa, and other serine
proteases in the coagulation cascade.4 Heparin also binds
nonspecifically and independently of the pentasaccharide to
other plasma proteins, platelet-derived proteins, and tissue
and cellular sites.5,6
We developed a probe that displaces heparin from
plasma proteins, which allows us to determine the role of
heparin-binding proteins in the mechanism of heparin re-
bound. We have prepared a heparin with virtually no affinity
to AT by chemical modification.7 When added in excess to
plasma, this low-affinity heparin is able to displace antico-
agulantly active heparin from plasma proteins, which is then
measured in an anti-factor Xa heparin assay.8 In a previous
study,9 we employed this low-affinity heparin to study hep-
arin rebound in 16 patients undergoing elective cardiac
surgery. After neutralization with protamine sulphate the
activated clotting time returned to baseline values. How-
ever, heparin activity measured as anti-factor Xa activity
was consistently elevated for the first 6 hours postopera-
tively. Anti-factor Xa activity after the addition of low-
affinity heparin to displace protein-bound heparin was mea-
surable in all patients and was 3- to 4-fold greater,
indicating that a pool of heparin remained in the circulation
for a number of hours postoperatively despite reversal with
protamine sulphate. Postoperative blood loss correlated
with postoperative heparin anticoagulant activity, suggest-
ing that the heparin that remained after protamine sulphate
neutralization was sufficient to impair hemostasis and pro-
mote postoperative hemorrhage.
Excessive postoperative hemorrhage continues to com-
plicate cardiac surgery. Bleeding is caused by a combination
of incomplete surgical hemostasis and an acquired hemo-
static defect.10 The nature of the acquired hemostatic defect
has been the subject of considerable controversy. The con-
TABLE 1. Patient characteristics of the study groups
Protamine Placebo
Number of patients 152 148
Age (y) 62  10 61  9.7
Men/women (%) 79/21 76/24
Body surface area (m2) 1.96  0.18 1.92  0.19
CABG/valves (%) 88/12 88/12
Combined CABG and valves 0 0
Cardiopulmonary bypass time (min) 88  27 85  28
CABG, Coronary artery bypass grafting.
Values are mean  SD.tribution of heparin rebound to postoperative bleeding has
212 The Journal of Thoracic and Cardiovascular Surgery ● Augunot been elucidated. Our studies have provided a plausible
explanation for the mechanism for heparin rebound and
have suggested a strategy for its elimination. One approach
to reduce postoperative bleeding would be to use a contin-
uous infusion of protamine after surgery to inactivate the
heparin that dissociates from cellular and protein binding
sites. The adverse cardiovascular effects of protamine11
should be minimal if the protamine is infused at a slow rate.
The aim of the present study was to determine whether
heparin rebound can be eliminated by additional treatment
with protamine sulphate for 6 hours postoperatively and
whether this protocol can result in the reduction in postop-
erative bleeding.
Methods
Trial Design and Patient Population
The study was conducted as a double-blind, randomized trial.
Three hundred patients undergoing elective cardiac surgery were
enrolled in the preoperative clinic over a period of 12 months.
These patients signed a consent form that was approved by the
Institutional Review Board. Patients were randomized by the phar-
macist to receive either a continuous intravenous infusion of
protamine sulphate (25 mg/h) for 6 hours postoperatively or saline
placebo according to a randomization table. The protamine dose
was chosen based on a pilot study that showed 25 mg/h markedly
reduced heparin levels over this time interval. Our earlier study9
suggested that the infusion should be given for at least 6 hours
after surgery. The primary outcome of the study was clinically
important postoperative bleeding that we defined as the need for
transfusion of 4 or more units of blood. The secondary outcome
was postoperative mediastinal blood loss. Our sample size esti-
mates suggested that 150 patients/group would have a 90% power
of detecting a 50% reduction in patients requiring 4 or more units
of blood transfusion with an alpha of .05 in a 2-tailed test.
Heparin and Protamine Management
Heparin (Hepalean; Organon Teknika, Toronto, Canada) was
given at an initial dose of 400 U/kg to achieve an activated clotting
time (ACT) greater than 400 seconds. Cardiopulmonary bypass
was instituted with an ascending aortic cannula and a 2-stage right
atrial cannula in most patients. The pump circuit employed a
semi-porous membrane oxygenator and was primed with Ringer’s
lactate solution. Moderate systemic hypothermia (28°C-32°C) was
maintained during the aortic crossclamp period. After discontinu-
ation of cardiopulmonary bypass, heparin was reversed with a
TABLE 2. Adverse events
Outcome Protamine Placebo P
Reoperation for bleeding 1 (0.7%) 2 (1.3%)
Protamine given for bleeding 12 (7.9%) 32 (21.6%) .001
Myocardial infarction 2 (2.6%) 3 (2.0%)
Mortality 2 (1.3%) 1 (0.7%)
Deep vein thrombosis/pulmonary
embolus/stroke
0 0bolus of protamine sulphate using the heparin-ACT dose-response
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Pcurve method to determine the dosage of protamine. Additional
small doses of protamine were administered in some patients to
return the ACT to preheparin values. The infusion of the test
solution was initiated within 15 minutes of protamine reversal.
Postoperative Management
Patients enrolled in the study followed standardized guidelines for
volume replacement and blood transfusions. The pulmonary cap-
illary wedge pressure was maintained at appropriate levels by
infusions of albumin or crystalloid. Hemoglobin concentrations
were obtained at 1, 3, 12, and 24 hours postoperatively. Packed red
cells were transfused to maintain the hemoglobin between 80 and
90 g/L. Blood loss through the mediastinal tubes was measured
and reinfused into the patient for up to 12 hours postoperatively.
Aliquots of the drainage fluid were taken for hematocrit determi-
nations using standard techniques. Clinically significant coagula-
tion defects were treated by infusions of protamine, fresh-frozen
plasma, or platelets when chest tube drainage fluid exceeded 150
mL/h. We employed the following guidelines for clinically signif-
icant defects: for extra protamine, thrombin clotting times (TcT, 2
units)  35 seconds; for plasma, an international normalized ratio
 1.5; and for platelets, a count of 80,000. Pharmacological
agents such as aprotinin, aminocaproic acid, and desmopressin
were not employed in the patients.
Anticoagulant Assays
A baseline blood sample was collected from the radial arterial line
Figure 1. The effect of protamine infusion on the thrombprior to heparin administration. Timed blood samples were ob-
The Journal of Thoracitained hourly between 1 and 6 hours and at 12, 18, and 24 hours
after protamine reversal also through the radial arterial line. Blood
was collected into tubes containing buffered sodium citrate (Va-
cutainer, Becton Dickinson, Mississauga, Canada). Platelet-poor
plasma (PPP) was prepared by centrifugation at 2000g at room
temperature for 15 minutes. The PPP was stored in polypropylene
tubes at 70°C until used.
Heparin concentrations were measured as anti-factor Xa activ-
ity based on the method of Teien and Lie.12 The Stachrom heparin
kit from Diagnostica Stago (Wellmark Diagnostics, Guelph, Can-
ada) was modified for use on the Cobas Bio centrifugal analyzer
(Roche Diagnostics, Etobicoke, Canada). Pooled PPP to which
known concentrations of unfractionated heparin (Hepalean, Or-
ganon Teknika) were added were used as standards. TcTs (2 units)
were performed on the LaBor Coa System (Fisher Scientific,
Toronto, Canada) using bovine thrombin (Thrombostat; Parke-
Davis, Scarborough, Canada). All anticoagulant assays were per-
formed in duplicate.
Low-affinity heparin was used as a probe to determine the
extent to which anticoagulantly active heparin binds to plasma
proteins other than AT. Low-affinity heparin was prepared from
unfractionated porcine mucosal heparin (178 IU/mg, Sigma Chem-
ical Co, St Louis, Mo) by periodate oxidation and borohydride
reduction according to the method of Casu and colleagues13 with
minor modifications.7 This chemical modification destroys the
ability of unfractionated heparin to bind to AT but preserves the
molecular size range and charge density of the parent molecule.
otting time (TcT). Data are expressed as mean SEM.in clThe low-affinity heparin measured 1.0 U/mg of anti-factor Xa
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centration of 45 ug/mL to displace anticoagulantly active heparin
from plasma protein binding sites8 and the anti-factor Xa activity
was measured again. This in vitro assay may not reflect the amount
of heparin bound to endothelium in vivo.
Statistics
Chi-square analysis was used to analyze categorical data. An
independent 2-sample t test was employed to analyze continuous
data. Results are expressed as mean  standard deviation unless
otherwise indicated.
Results
Patient Characteristics
A total of 152 patients were randomized to receive extra
protamine (25 mg/h) for 6 hours postoperatively and 148
received saline placebo. The patient characteristics are
shown in Table 1. No important differences in patient char-
acteristics were found between the treatment and placebo
groups.
The amount of heparin employed was 33,000  5000
units in the protamine group, which was not significantly
different from 33,000  6000 units in the placebo group (P
 .476). Similarly, there was no difference between the
amount of protamine required to return the ACT to prehe-
Figure 2. The effect of protamine infusion on heparin le
are expressed as mean  SEM.parin levels prior to the infusion of the test solutions (167
214 The Journal of Thoracic and Cardiovascular Surgery ● Augu44 mg in the protamine group vs 172  42 mg in the
placebo group, P  .297).
There were no adverse events attributable to the extra
protamine administered postoperatively over 6 hours. No
important differences were detected in the rate of reopera-
tion, myocardial infarction, or mortality between the two
groups. However, the number of patients requiring small
amounts of protamine to control excessive bleeding was
higher in the placebo group (Table 2). Most patients re-
ceived 25 to 50 mg of protamine.
Reappearance of Anticoagulant Activity (Heparin
Rebound)
Despite returning the ACT to baseline levels following
surgery, there was reappearance of anticoagulant activity
indicative of heparin rebound as demonstrated by both the
TcT and anti-factor Xa assay in the placebo group. As
shown in Figure 1, the postoperative TcTs of the placebo
group were consistently higher than that of the treatment
group between 1 and 5 hours. In contrast, the TcTs of the
group that received the extra protamine were within normal
reference intervals (20-30 seconds) and significantly lower
(P .001) for the same time frame. Unexpectedly, once the
infusion of extra protamine was stopped, the TcTs became
Heparin was measured as anti-factor Xa activity. Datavels.higher in the treatment group between 9 and 18 hours
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Activated partial thromboplastin times (APTTs) were mea-
sured at 1 and 4 hours postoperatively as part of regular
patient care. The APTT values in the placebo group were
significantly higher than in the protamine group at 1 and 4
hours (40.5  13.5 seconds vs 32  5.2 seconds at 1 hour,
P  .001, and 38.0  13.5 seconds vs 27.8  13.5 seconds
at 4 hours, P  .001).
Heparin concentrations measured as anti-factor Xa ac-
tivity are shown in Figure 2. In the placebo group, heparin
levels were elevated at 1 hour post–protamine neutralization
and remained so for 6 hours (between 0.03 and 0.05 U/mL).
In contrast, the heparin concentrations in the group who
received extra protamine were virtually undetectable (less
than 0.002 U/mL) and significantly lower (P  .001) than
that of the placebo group. The baseline samples were taken
from the radial arterial line that was flushed with a solution
containing small amounts of heparin. This explains the
measurable anti-factor Xa levels found in these samples.
The reappearance of small amounts of heparin following the
cessation of the infusion of extra protamine was also de-
tected by anti-factor Xa levels between 9 and 18 hours
Figure 3. The effect of protamine infusion on hepari
heparin was used to displace anticoagulantly active he
as mean  SEM.postoperatively.
The Journal of ThoraciProtein-Bound Heparin
Low-affinity heparin was added to the samples to determine
the amount of anticoagulantly active heparin bound nonspe-
cifically to plasma proteins other than AT. As shown in
Figure 3, there was significantly more heparin bound to
plasma proteins in the placebo group compared with the
protamine group during the first 6 hours. Whereas the anti-
factor Xa levels in the placebo group reached peak levels of
0.25 U/mL at 3 and 4 hours, the levels found in the prota-
mine group were consistently below 0.05 U/mL. These
results indicate that the infusion of additional protamine was
able to reduce dramatically both free and protein-bound
heparin. Once the infusion of additional protamine was
stopped, the amount of heparin bound to plasma proteins
became higher in the treatment group between 9 and 18
hours. This observation is consistent with the increased
TcTs and anti-factor Xa levels described above.
Blood Loss
The infusion of extra protamine for 6 hours postoperatively
was able to reduce mediastinal blood loss. As shown in
Figure 4, A, the hourly blood loss in the protamine group
und nonspecifically to plasma proteins. Low-affinity
from plasma protein binding sites. Data are expressedn bo
parinwas generally lower than the placebo group at all time
c and Cardiovascular Surgery ● Volume 128, Number 2 215
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between the 2 groups was modest (5-30 mL per hour on
average) but was significantly different at 3 and 4 hours
Figure 4. The effect of protamine infusion on blood los
expressed as mean  SEM. Values in parentheses
between group means.postoperatively. When expressed as cumulative blood loss
216 The Journal of Thoracic and Cardiovascular Surgery ● Augu(Figure 4, B), the amount collected during the first 12 hours
was significantly lower in the protamine group (525  322
mL) than in the placebo group (608  385 mL). The mean
hourly blood loss; (B) cumulative blood loss. Data are
sent the 95% confidence intervals of the differences: (A)
reprereduction in mediastinal blood loss was approximately 80
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treatment group was still lower than the placebo group (848
 383 vs 935  480 mL) but the difference was no longer
significant. There were no important differences in the he-
matocrit of the mediastinal drainage fluid or in the patients’
hemoglobin values when measured at various times post-
operatively. For example, at 1 hour the hematocrit in the
chest tube fluid of the placebo group was 0.174 0.051 and
0.178  0.042 in the protamine group. At 9 hours, the
hematocrits were 0.115 0.064 and 0.121 0.064, respec-
tively. By 12 hours, the hematocrit of the fluid had fallen to
0.076  0.056 in the saline group and 0.074  0.059 in the
Figure 5. The effect of protamine infusion on transfu
plasma. Data are expressed as mean  SEM. Values in
difference between group means.protamine group.
The Journal of ThoraciTransfusions
The transfusion requirements are shown in Figure 5. The
total volume of packed cells administered to the protamine
group was the same as in the placebo group. Sixty-eight
percent of patients in both groups received packed cells. For
these transfused patients, the protamine group received 950
mL/patient of packed cells compared to 940 mL/patient in
the saline group. Although there was a trend for the prota-
mine group to need less fresh-frozen plasma, there was no
significant difference in cumulative plasma transfusion be-
tween the 2 groups. Fifteen percent of patients in the pro-
tamine group received fresh-frozen plasma compared with
requirements: (A) packed red cells; (B) fresh-frozen
ntheses represent the 95% confidence intervals of thesion
pare20% in the saline group. Of the patients transfused, the
c and Cardiovascular Surgery ● Volume 128, Number 2 217
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plasma versus 690 mL/patient in the saline group. No pa-
tients in the protamine group received platelet transfusions,
although 7% of patients in the placebo group received an
average of 250 mL/patient of platelets.
Discussion
In this double-blind, randomized study, we have confirmed
our earlier observations regarding heparin rebound9 but in a
much larger patient group. Thus, following heparinization
for cardiopulmonary bypass surgery and after neutralization
with protamine, heparin rebound was observed in virtually
every patient in the placebo group. We propose the follow-
ing mechanism to explain heparin rebound after protamine
neutralization. Heparin binds to AT, to other plasma pro-
teins, to vascular wall matrix proteins, and to endothelial
cells where it distributes in an equilibrium that is dependent
on the relative affinity of these proteins for heparin binding
and the concentrations of the proteins. When protamine is
administered, it binds to both unbound heparin and heparin
that becomes dissociated from tissue and protein binding
sites. The resulting heparin/protamine complexes14 are then
cleared from the circulation. Heparin rebound occurs be-
cause not all heparin is bound to and cleared by protamine.
Rather, a proportion remains bound nonspecifically to
plasma proteins and vascular cells, which provides a reser-
voir of heparin that dissociates over time and produces an
anticoagulant effect when it binds to AT.9
The reappearance of anticoagulant activity in the saline
placebo group was indicated by the prolongation of the TcT.
The anticoagulant effect was due to heparin because of its
effect on anti-factor Xa activity. There was also consider-
able heparin bound nonspecifically to plasma proteins other
than AT. This proportion of protein-bound heparin was
unmasked by using low-affinity heparin to displace antico-
agulantly active heparin from protein-binding sites.7-9 Some
of these heparin-binding proteins are acute phase proteins.
A number of acute phase reactants including fibronectin,15
vitronectin,16 and von Willebrand factor17 are known to
bind heparin. Cardiopulmonary surgery is an inflammatory
condition that can stimulate the synthesis of acute phase
proteins that could contribute to increased protein binding.18
In contrast, the postoperative infusion of protamine (25
mg/h for 6 hours) was able to eliminate heparin rebound
almost completely. The TcTs fell to within normal reference
intervals (20-30 seconds). The heparin concentrations mea-
sured as anti-factor Xa activity were virtually undetectable
and the amount of protein-bound heparin was also dramat-
ically lower in the protamine group. The infusion of small
amounts of protamine did not lead to an increase in adverse
outcomes.
Unexpectedly, following the termination of the prota-
mine infusion, there was a small but detectable reappear-
218 The Journal of Thoracic and Cardiovascular Surgery ● Auguance of anticoagulant activity between 9 and 18 hours. This
was reflected by increased TcTs, heparin concentration, and
protein-bound heparin. It is possible that the extra prota-
mine administered was insufficient to neutralize all the
heparin from plasma protein and tissue binding sites be-
cause the infusion was terminated prematurely. The phar-
macokinetic half-life of protamine is very short (approxi-
mately 5 minutes),19 and protamine may no longer be
present to bind heparin after it is slowly released from
non-AT binding sites. Second, heparin has been shown to
bind to endothelial cells.20,21 A proportion of the bound
molecules are internalized and depolymerized into smaller
molecular size fragments. Some of the internalized heparin
is then secreted in depolymerized form.22,23 The persistence
of anti-factor Xa activity for several weeks following low-
molecular-weight heparin treatment has been described.24
The liver and kidneys were implicated as the tissues that
sequester some of the injected drug, which gives rise to
anticoagulantly active material by degradation and secretion
into the plasma. This tissue reservoir may be inaccessible to
protamine. Another factor may be the inability of protamine
to completely neutralize low-molecular-weight heparin.25
These reasons may help to explain the reappearance of
anticoagulant activity once the protamine infusion was
stopped. The increase in anticoagulant activity, however,
did not increase postoperative bleeding.
The extra protamine administered decreased postopera-
tive bleeding although the magnitude of the reduction was
rather modest. The reduced bleeding did not translate into
decreased transfusion requirements. Excessive postopera-
tive bleeding after coronary artery bypass surgery is thought
to be a multifactorial process. In addition to heparin re-
bound, hyperfibrinolysis26,27 and an acquired platelet de-
fect10 are considered to be the main contributors to postop-
erative bleeding. Antifibrinolytic agents have been
employed to reduce postoperative bleeding. These include
the protease inhibitor aprotinin and transexamic acid or its
analog, epsilon-aminocaproic acid.28,29 These drugs have
been shown to reduce bleeding by approximately 30% to
40% and to reduce allogeneic blood transfusion by a similar
amount.30 In comparison, our strategy of employing extra
protamine to eliminate heparin rebound resulted in only a
13% reduction in bleeding with no change in transfusion
requirements. Our results suggest that heparin rebound is a
minor contributor to postoperative bleeding and that activa-
tion of the fibrinolytic system plays a greater role.
A potential weakness of our study was that extra prota-
mine (25-50 mg) was given postoperatively to treat clini-
cally significant bleeding in both groups. This cointerven-
tion, the extra protamine, was administered concurrently as
required along with the blinded study drug. That explains
why the placebo group got more protamine for this purpose
because they received saline only. We could not ethically
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Pwithhold extra protamine to correct coagulation defects.
This may potentially diminish the observed differences in
outcomes between the 2 groups. If the unavoidable coint-
ervention had not occurred, the outcome of the study may
have been different.
In summary, we have demonstrated that heparin rebound
can be virtually eliminated by giving extra protamine for 6
hours during the postoperative period. The procedure is
inexpensive. The elimination of heparin rebound led to a
statistically significant reduction in postoperative bleeding
but the amount of the reduction was modest and did not
reduce blood transfusions. The protamine infusion reduces
bleeding and appears to be safe although there is insufficient
data in the study to rule out uncommon drug-related adverse
events. Additional protamine is helpful in the setting of
excessive bleeding with evidence of heparin rebound and
may be beneficial when used routinely following cardiopul-
monary bypass.
K.H.T.T. and E.Y. contributed equally to this study and share
first authorship. We acknowledge the participation in this study of
the cardiac surgeons, nurses, perfusionists, and the staff of the
intensive care unit.
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